Tomorrow Investor

Volatus Aerospace Awarded $9M Defence Contract from NATO Partner, Accelerating Growth in Uncrewed Systems

Volatus Aerospace Secures $9M Defence Contract from NATO Partner | GlobeNewsWire

MONTRÉAL, Dec. 15, 2025 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABB.F) (“Volatus” or “the Company”), a leader in uncrewed, aerial, and defense technology solutions, is pleased to announce that it has been awarded a defence contract valued at up to CAD $9 million to supply an allied defence organization with a next-generation interim training system for Intelligence, Surveillance, and Reconnaissance (ISR) operations. The award is structured over two years, with an initial tranche of approximately $4.5 million scheduled for delivery in Q1 2026.

This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.

Brief Summary

Volatus Aerospace Inc. has just landed a significant $9 million defence contract to enhance NATO operations. This contract will allow Volatus to supply an advanced training system aimed at bolstering Intelligence, Surveillance, and Reconnaissance (ISR) capabilities.

  • $9 million contract awarded to Volatus Aerospace.
  • Initial delivery tranche of $4.5 million in Q1 2026.
  • Contract enables advanced ISR training systems.
  • Strategic partnership with NATO.
  • Further expands Volatus’ market reach and capabilities.

Why it matters: This contract not only solidifies Volatus’ position as a leader in uncrewed systems but also highlights its growing significance in defense operations.

Read the Full Article

This is a summary of the press release. For the complete article and any additional details, please visit the original source.

Read Full Article

Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.

Tomorrow Investor
The Tomorrow Investor

Markets research for retail investors

Independent coverage of small-cap equities, biotech catalysts, and emerging market opportunities.